The Expression and Regulation of Nitric Oxide Synthase in Human Osteoarthritis-affected Chondrocytes: Evidence for Up-regulated Neuronal Nitric Oxide Synthase

By Ashok R. Amin,* Paul E. Di Cesare,‡ Pranav Vyas,* Mukundan Attur,* Edith Tzeng,§ Timothy R. Billiar,§ Steven A. Stuchin,§ and Steven B. Abramson*II

From the Departments of *Rheumatology and Orthopaedic Surgery, Hospital for Joint Diseases Orthopaedic Institute, New York 10003; the Departments of §Pathology and Medicine, New York University Medical Center, New York 10016; and the *Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15261

Summary

Classically, osteoarthritis (OA) has been considered a noninflammatory disease. However, the detection of selected inflammatory mediators in osteoarthritic fluid, in the absence of significant inflammatory cell infiltrate, is increasingly appreciated. We sought to identify the inflammatory component in human OA-affected cartilage that may be involved in cartilage damage/destruction. Using Western blot analysis and an antibody to the conserved region of nitric oxide synthase (NOS), we have observed up-regulation of NOS, one of the "key players" of inflammation, in chondrocytes of OA-affected patients. Remarkably, none of the cartilage samples examined from normal joints demonstrated detectable amounts of this NOS. Western blot analysis using the same α-NOS antibody indicated that this NOS from OA-affected cartilage (OA-NOS) was larger in size than (and distinct from) transfected human hepatocyte or murine inducible NOS (iNOS) (150 versus 133 kD) and similar in size to neuronal constitutive NOS (ncNOS). Antibodies specific for iNOS showed binding to murine and human iNOS but not to OA-NOS, endothelial constitutive NOS, or ncNOS. Antibodies specific for ncNOS bound to ncNOS and also to OA-NOS, but not to murine or human iNOS or endothelial constitutive NOS. Incubation of OA cartilage in serum-free medium resulted in spontaneous release, for up to 72 h, of substantial amounts of nitrite (up to ∼80 μM/100 mg wet tissue), which could be inhibited by at least 80% with various inhibitors of iNOS, including inhibitors of protein synthesis and transcription factor NF-κB, but which (unlike murine macrophage iNOS) was not sensitive to hydrocortisone or TGF-β. Exposure of OA-affected cartilage to interleukin 1β, tumor necrosis factor-α, and lipopolysaccharide resulted in ∼20–50% augmentation of nitrite accumulation, which was also sensitive to cycloheximide and pyrrolidine dithiocarbamate. Hence, our data indicate that OA-NOS (based on immunoreactivity and molecular weight) is similar to ncNOS and that it releases nitric oxide, which may contribute to the inflammation and pathogenesis of cartilage destruction in OA.
nitric oxide synthase (cNOS) is a key regulator of homeostasis, whereas the generation of NO by the inducible NOS (iNOS) plays an important role in inflammation, host defense responses, and tissue repair (5). iNOS has been found in various cell types (5). Exposure of rabbit (6) and human chondrocytes (4, 5) to cytokines and endotoxin leads to accumulation of nitrite in the medium. Studies involving animal arthritis models and analysis of human synovial fluids have implicated NO in the pathogenesis of arthritis (7, 8). Induction of arthritis in rodent models resulted in increased production of nitrite before the onset of clinical symptoms. The appearance of articular symptoms and joint degeneration in these animal models could be inhibited by administration of an NOS inhibitor (7). Neuronal cNOS (ncNOS) has been shown to be present in several cell types (5). Its function outside the vicinity of the neuronal system has recently been recognized, where ncNOS-knockout mice show abnormalities in the gastrointestinal tract similar to pyloric stenosis (9).

Increased concentrations of nitrite have been reported in human synovial fluid from RA and OA patients, suggesting that NO may be a mediator of inflammation in both diseases (8). In the present study, we sought to identify the source of NO in OA and to characterize the respective NOS. In this paper, we report the following: (a) OA-NOS expressed under pathological conditions is similar to ncNOS (and distinct from iNOS) and is not detected in normal cartilage; (b) human OA cartilage spontaneously releases micromolar concentrations of NO; and (c) the prolonged (72-h) accumulation of NO by OA cartilage in ex vivo experiments is indicative of NO up-regulating factor(s) within the cartilage, and this phenomenon is sensitive to inhibitors of protein synthesis and of the transcription factor NF-κB, but not to TGF-β or hydrocortisone.

**Materials and Methods**

**Reagents and Cell Lines.** A macrophage-like cell line, RAW 264.7, was obtained from American Type Culture Collection (Rockville, MD). Monoclonal α-mouse macrophage iNOS Ab, monoclonal α-human endothelial cNOS (ecNOS) Ab, and polyclonal α-human ncNOS Ab were obtained from Transduction Laboratories (Lexington, KY); specific polyclonal α-mouse macrophage iNOS Ab were from Affinity Bioreagents, Inc. (Ne�anic Station, NJ); protease inhibitors, hydrocortisone, cycloheximide, pyrrolidine dithiocarbamate (PDTC), aminoquinidine and LPS were from Sigma Chemical Co. (St. Louis, MO); human IL-1B, TGF-β, and TNF-α were from Fisher Scientific Co. (Pittsburgh, PA); and HN2-monomethyl-L-arginine monocrotate (L-NMMA) from Cyclops Biocolloidal Corp. (Salt Lake City, UT).

**Isolation of Bovine Chondrocytes.** Bovine cartilage was washed after removing the perichondrium, cut into small pieces, and digested with pronase (0.1%) in PBS for 30 min, followed by digestion with collagenase P (0.1%) for 12-16 h in F-12 medium. Cells were then washed and resuspended in the respective media for experiments.

**Extraction of Human Chondrocyte NOS and Western Blotting.** OA cartilage was obtained from OA patients who underwent knee replacement surgery and were free of steroidal/nonsteroidal antiinflammatory drugs for at least 2 wk before surgery; nonarthritic normal knee cartilage was obtained from the Musculoskeletal Transplant Foundation (Shrewsbury, NJ) within 24 h of death, or from autopsies the same day. Slices of articular cartilage affected by OA (and normal controls) were frozen at −70°C, milled to fine particles in liquid nitrogen, and sequentially extracted (10 ml/g wet weight tissue) with neutral salt buffer (Tris-HCl:saline) containing protease inhibitors (1 mM PMSF, 2 mM N-ethylmaleimide, and 0.025 mg/ml leupeptin), followed with the same buffer containing 10 mM EDTA, with 4 M guanidine-HCl, and then with a detergent buffer containing 10% SDS with protease inhibitors. Samples were run on 9% or 4-15% gradient SDS-PAGE gels under nonreducing conditions, transferred to nitrocellulose, and Western blotted with the required α-NOS Ab. Bound antibody was detected by a secondary antibody conjugated with horseradish peroxidase, and developed using the enhanced chemiluminescence Western blotting system (Amerham Corp., Arlington Heights, IL) on x-ray film (Xomatic; Eastman Kodak Co., Rochester, NY).

**Isolation of Recombinant Human Hepatocyte iNOS.** Human hepatocyte iNOS was obtained from 3T3 fibroblasts (National Institutes of Health, Bethesda, MD) transduced with a retrovirus carrying the human hepatocyte iNOS cDNA. The construction and characterization of the stable expression of iNOS in these cells have been reported by Tzeng et al. (10).

**Results and Discussion**

We initiated our studies by standardizing conditions to extract NOS directly from OA-affected articular cartilage before cell isolation. OA cartilage was sequentially extracted with various buffers and Western blotted using a monoclonal α-mouse macrophage iNOS Ab that cross-reacts with human hepatocyte iNOS. Approximately 90% of NOS from OA-affected cartilage (OA-NOS) was present in the neutral salt fraction, ~10% was seen in the EDTA-containing buffer, and no OA-NOS was detected in either the guanidine or detergent extracts (Fig. 1a).

To further evaluate the expression of OA-NOS, equal amounts of extracts from OA-affected and nonarthritic articular cartilage were subjected to Western blot analysis using the same α-mouse macrophage iNOS mAb. All 12 patients with OA demonstrated expression of a 150 kD NOS, whereas no NOS was detected from nonarthritic control cartilage (Fig. 1b). The OA-NOS detected in all 12 patients had a Mr of 150 kD, which was distinct from mouse macrophage iNOS. This experiment demonstrates that, under pathological conditions, the OA-affected cartilage expresses an isoform of NOS distinct in size from iNOS. The absence of NOS activity (nitrite release) in normal resting human chondrocytes has also been reported by other investigators (4), in accord with our own observation that expression of iNOS or OA-NOS is not detectable in normal cartilage or chondrocytes.

The Mr of the human OA-NOS was further compared with other known isoforms of NOS by Western blot analysis (Fig. 2). At the same time, various antibodies were tested for their cross-reactivity with OA-NOS and other known isoforms of NOS. As expected, a monoclonal α-mouse macrophage iNOS Ab (raised against the peptide
Figure 1. (a) Western blot analysis of NOS on 9% SDS-PAGE. Various extracts from OA cartilage were prepared sequentially as described in Materials and Methods. Lane 1, neutral salt extract; lane 2, EDTA extract; lane 3, 4 M guanidine-HCl extract; lane 4, detergent extract. (b) Neutral salt extracts from knee articular cartilage of 12 OA patients (lanes 2–13) and 7 nonarthritic (normal) individuals (lanes 14–20). Lane 1 shows iNOS from murine macrophages (RAW 264.7) stimulated with LPS for 24 h. iNOS was detected with an α-murine macrophage iNOS mAb. Extracts were prepared from equal wet weight of cartilage samples, and equal amounts were loaded in each lane.

sequence 961–1144), showed reactivity with 133-kD human hepatocyte iNOS and murine macrophage iNOS. This monoclonal α-mouse macrophage iNOS Ab also bound to 150-kD human OA-NOS and rat ncNOS (Fig. 2 a), thus indicating that this α-iNOS mAb also cross-reacts with ncNOS. However, a polyclonal Ab raised against the amino acid sequence 1095–1289 from human ncNOS bound to 150-kD human OA-NOS (and also, as expected to 150-kD rat ncNOS), but did not detect the 133 kD iNOS (Fig. 2 b). A polyclonal α-mouse macrophage iNOS Ab (raised from the peptide sequence 1131–1144) bound to 133-kD mouse macrophage and human hepatocyte iNOS, but not to 150-kD human OA-NOS or rat ncNOS (Fig. 2 c). None of these antibodies showed any reactivity with extracts obtained from human umbilical vein endothelial cells (HUVEC). This HUVEC extract was tested by probing it with an α-ecNOS antibody, which showed a 133-kD ecNOS band (data not shown). The monoclonal α-mouse macrophage iNOS Ab also cross-reacts with 133-kD bovine and rodent chondrocyte iNOS (unpublished data). These results show that the 150-kD human OA-NOS and ncNOS, which are similar in size (Fig. 2), are distinct from iNOS from human hepatocytes (native and transfected), human B cells, bovine and rodent chondrocytes, and murine macrophages (10–12), which are 133 kD (Fig. 2). We conclude that the OA-NOS is similar to ncNOS, based on their similar size, their shared reactivity to antibodies specific for 133-kD iNOS, and their lack of reactivity to polyclonal α-iNOS antibodies specific for the 133-kD iNOS.

These observations pose an obvious question: What is the role of human chondrocyte iNOS in OA? It should be noted that two groups (13, 14) have cloned the human chondrocyte iNOS from cDNA libraries prepared from (in vitro) IL-1–stimulated human chondrocytes. These libraries were screened with a degenerative oligonucleotide or murine iNOS cDNA. The OA-NOS seems to be distinct from the human chondrocyte iNOS. Apparently, human chondrocytes express at least two isoforms of NOS that are differentially regulated, namely iNOS (13, 14) and OA-NOS. Therefore, we propose that the known NO-mediated chondrocyte dysfunction that could lead to OA is the result of up-regulation of OA-NOS.

To evaluate the biological activity of OA-NOS, we standardized parameters to set up organ culture of OA-affected cartilage in ex vivo conditions. We observed that ~50–100 mg of OA cartilage from various patients released ~10–80 μM of nitrite after 48 h in serum-free medium, which could be inhibited by >90% with 500 μM L-NMMA (Fig. 3 a) or aminoguanidine (not shown). Interestingly, in a single case in which cartilage was obtained from both knees, similar levels of nitrite were observed (Fig. 3 a, patient samples Nos. 3a and 3b). These experiments suggest that OA-affected chondrocytes generate micromolar concentrations of NO that have been associated with degradation of articular cartilage (8). Exposure of the OA cartilage in vitro to pharmacological concentrations of IL-1β, TNF-α, and endotoxin resulted in a consistent increase in NO production at 24 h (Fig. 3 b) and a more pronounced effect at
placed in organ culture in 2 ml medium in the presence and absence (CONTROL) of 500 μM L-NMMA. One set of cultures was incubated with LPS, IL-1β, and TNF-α. Data are expressed as micromoles of nitrite released ± SD (n = 7). The P values between Control versus LPS-, IL-1β-, and TNF-α-treated cultures were: 1 <0.002; 2 <0.001. The P values between Control and L-NMMA-treated cultures were: 3a <0.056; 3b <0.001. The P values between cytokine plus endotoxin-treated cultures versus cycloheximide/PDTC was <0.013. Samples obtained at various time intervals were assayed for nitrite by modified Griess reaction (15) using an ELISA reader. The statistics were derived using unpaired Student's t test.

48 h (Fig. 3). The spontaneous release of NO could be inhibited by L-NMMA as in Fig. 3, a and b. Snyder and coworkers (16) have reported that neuronal NOS is induced in spinal neurons by traumatic injury. Furthermore, human chondrocytes exposed to exogenous NO, or cytokines and endotoxin (at concentrations used in this study), have demonstrated inhibition of growth, chemotactic responses to growth factors, proteoglycan synthesis, and induction of apoptosis (17-19, and unpublished data). Therefore, it is quite conceivable that the up-regulation of OA-NOS is triggered under pathological conditions such as OA, because nitrate levels in the serum of RA (0.44 μmol/liter) and OA (0.21 μmol/liter) patients were significantly elevated in comparison to normal controls (0.14 μmol/liter) (8), whereas synovial fluids from these RA and OA patients demonstrated significant mean nitrite levels of 0.91 and 0.35 μmol/liter, respectively. It should be noted that, unlike murine macrophages (11), human chondrocytes (10') stimulated with cytokines and endotoxin in vitro release nanomolar concentrations of nitrite (4, 20).

To further investigate the regulation of OA-NOS in OA cartilage, a time course release of nitrite was performed. OA cartilage incubated with serum-free medium demonstrated a steady accumulation of nitrite up to 72 h (Fig. 4, a), indicating that production of nitrite is “spontaneously” released and may be constantly stimulated in OA cartilage.

The spontaneous accumulation of nitrite by OA-affected cartilage was evaluated for its sensitivity to cycloheximide and NF-κB inhibitor PDTC. Addition of 3.5 and 17.5 μM
of cycloheximide to OA cartilage showed >90% inhibition of nitrite accumulation as compared with controls within 24 h. The data in Fig. 4b show a representative experiment in which addition of cytokines and endotoxin augmented the release of nitrite in the medium. Nitrite accumulation was significantly blocked by >90% in both the cytokine- and endotoxin-induced cartilage and control cartilage in the presence of cycloheximide or PDTC, thus indicating that the OA-affected chondrocyte NOS activity is sensitive to cycloheximide and PDTC with respect to production of nitrite in ex vivo cultures. The inhibition by PDTC and cycloheximide of nitrite accumulation in OA cartilage may be due to inhibition of de novo protein synthesis of OA-NOS itself, cofactors involved in the regulation of OA-NOS, or both—a hypothesis that must be tested. However, it should be noted that the human nNOS gene has two NF-κB-like sequences in the 5′ untranslated region (21). Incubation of OA-affected articular cartilage, either in basal medium alone or supplemented with BSA, had insignificant impact on the release of nitrite (data not shown). In similar and parallel experiments using normal adult bovine articular cartilage or murine RAW 264.7 cells, we did not observe any detectable amounts (>1 μM) of nitrite after 48 h (data not shown), indicating that the medium used in these experiments was devoid of any stimulating agent that may have contributed to the up-regulation of NOS in OA cartilage on days 2 and 3 in the ex vivo experiments. As expected, addition of LPS (100 ng/ml and 100 μg/ml) showed an accumulation of nitrite in the medium after 20 or 48 h in both murine RAW 264.7 cells and bovine articular cartilage, respectively (data not shown).

These studies also indicate that a PDTC/cycloheximide-sensitive “NO-up-regulating factor(s)” may be present within the OA cartilage. Potential up-regulator(s) of OA-NOS may be one or a combination of the following manifestations: (a) autocrine cytokines/growth factors produced by chondrocytes in OA cartilage; (b) interaction with cell surface receptor (glutamate receptors/CD53) or matrix components (fibronectin and collagen) that can modulate NOS (22, 23); (c) diffusion of soluble (paracrine) factors into the cartilage in vivo from other cellular sources of the intraarticular region (e.g., endothelial cells, lining of the synovial capillaries, local inflammatory cells, and/or synovial fibroblasts); (d) abnormal mechanical forces seen by the chondrocytes in the three-dimensional architecture, because shear stress is reported to release nitrite from articular chondrocytes (24).

We further evaluated the effect of hydrocortisone and TGF-β, known modulators of iNOS (5, 25), on OA-NOS expression in ex vivo conditions. Unlike the effects of cycloheximide and PDTC, there was no significant effect of 10 μM of hydrocortisone (10.3 ± 4.9) or 2.5 ng/ml of TGF-β (8.7 ± 2.3) on the spontaneous release of nitrite (9.6 ± 1.5 μM) from OA cartilage in organ cultures, whereas LPS-stimulated RAW 264.7 cells showed a significant decrease (6.4 ± 0.5 and 2.8 ± 0.7 μM; n = 3; P <0.001) in nitrite released in the presence of equivalent amounts of hydrocortisone and TGF-β, respectively (5, 25). These experiments show that some of the regulatory properties of OA-NOS are distinct from iNOS. This may be because the rodent chondrosarcomas express a 133 kD iNOS (Amin et al., unpublished data). Although TGF-β and hydrocortisone may not have a direct effect on OA-NOS expression, they are known to contribute to chondrogenesis and to repair and healing mechanisms in the cartilage (26). Furthermore, previous studies by Thorbecke and coworkers (27) have demonstrated that injecting mice with TGF-β suppresses collagen-induced arthritis, thus indicating that the role of TGF-β (other than its ability to suppress iNOS activity in the rodent system) may also be to suppress inflammatory processes such as infiltrating T cells. However, targeting of 133-kD iNOS for pharmacological intervention in animal models of arthritis in vivo, or bovine chondrocytes in vitro, should proceed with caution, keeping in mind the characteristic features of human OA-NOS.

In summary, articular chondrocytes are a source of increased levels of intraarticular NO that have been speculated in OA patients (8). Our data further support the notion that NO, a known inflammatory mediator, is released in sufficient quantities (4, 8) to cause chondrocyte dysfunction and to damage cartilage integrity, and thus may be one of the key mediators in the pathogenesis of OA. Further study of the mechanisms governing NOS expression and of the consequences of increased NO production by OA-affected cartilage will help to define potential targets for pharmacological intervention and gene therapy.

We thank the Musculoskeletal Transplant Foundation for providing normal human cartilage, and Dr. Anthony Recupero, Ms. Susan Pesce, and Dr. Frank McNeil for kindly providing antibodies, cytokines, and l-NMMA, respectively. We thank Ms. Ann Rupelforty typing and editing the manuscript.

This study was supported by institutional funds from the Hospital for Joint Diseases and, in part, by the Joseph and Sophia Abeles Foundation.

Address correspondence to Dr. Ashok Amin, Department of Rheumatology, Room 1600, Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003.

Received for publication 30 November 1994 and in revised form 16 June 1995.

2101 Amin et al. Brief Definitive Report
References

1. Hough, A.J. 1993. Pathology of osteoarthritis. In Arthritis and Allied Conditions. D.J. McCarr and W.J. Koopman, editors. Lea & Febiger, Philadelphia and London. 1699–1723.

2. Goldring, M.B. 1993. Degradation of articular cartilage in culture: regulatory factors. In Joint Cartilage Degradation. J.F. Woessner, Jr., and D.S. Howell, editors. Marcel Dekker, New York, Basel, and Hong Kong. 281–345.

3. Pelletier, J.P., P.J. Roughley, J.A. Di Battista, R. McCollum, and J. Martel-Pelletier. 1991. Are cytokines involved in osteoarthritic pathophysiology? Semin. Arthritis Rheum. 20 (6 Suppl. 2):12–25.

4. Palmer, R.M.J., M.S. Hickery, I.G. Charles, S. Moncada, and M.T. Bayliss. 1993. Induction of nitric oxide synthase in human chondrocytes. Biochem. Biophys. Res. Commun. 193: 398–405.

5. Nathan, C., and Q. Xie. 1994. Nitric oxide synthases: role, taws, and controls. Cell 78:915–918.

6. Stadler, J., M. Stefanovic-Racic, T.R. Billiar, R.D. Curran, L.A. McIntyre, H.J. Georgescu, R.L. Simmons, and C.H. Evans. 1991. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J. Immunol. 147:3915–3920.

7. McCartney-Francis, N., J.B. Allen, D.E. Mikel, J.E. Albina, Q.W. Xie, C.F. Nathan, and S.M. Wahl. 1993. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 178:749–754.

8. Farrell, A.J., D.R. Blake, R.M.J. Palmer, and S. Moncada. 1992. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic disease. Ann. Rheum. Dis. 51:1219–1222.

9. Huang, P.L., T.M. Dawson, D. Bredt, S.H. Snyder, and M.C. Fishman. 1993. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 75:1273–1286.

10. Tzeng, E., T.R. Billiar, P.D. Robbins, M. Loftus, and D.J. Stuehr. 1995. Expression of human inducible NO synthase in a tetrahydrobiopterin-deficient cell line: tetrahydrobiopterin is required for assembly into an active dimer. Endotheleum 3(Suppl.):S29.

11. Xie, Q.W., H.J. Cho, J. Calayac, R.A. Mumford, K.M. Swiderek, T.D. Lee, A. Ding, T. Troso, and C. Nathan. 1992. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (Wash. DC). 256: 225–228.

12. Mannick, J.B., K. Asano, K. Izumi, E. Kieff, and J.S. Stamler. 1994. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79: 1137–1146.

13. Maier, R., G. Bilbe, J. Rediske, and M. Lotz. 1994. Inducible nitric oxide synthase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochim. Biophys. Acta 1208:145–150.

14. Charles, I.G., R.M.J. Palmer, M.S. Hickery, M.T. Bayliss, A.P. Chubb, V.S. Hall, D.W. Moss, and S. Moncada. 1993. Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc. Natl. Acad. Sci. USA. 90:11419–11423.

15. Green, L.C., D.A. Wagner, J. Glogowske, P.L. Skipper, S.L. Wishnow, and S.R. Tannenbaum. 1982. Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal. Biochem. 12b:12299–12302.

16. Wu, W., F.J. Liuzzi, F.P. Schinco, A.S. Depto, Y. Li, J.A. Mong, T.M. Dawson, and S.H. Snyder. 1994. Neuronal nitric oxide synthase is induced in spinal neurons by traumatic injury. Neuroscience. 61:719–726.

17. Clancy, R.M., S. Frenkel, J. Ricci, and S.B. Abramson. 1994. Effect of nitric oxide on chondrocyte migration and colony formation. Arthritis & Rheum. 37(Suppl. 9):S293. (Abstr.)

18. Taskiran, D., M. Stefanovic-Racic, H. Georgescu, and C.E. Evans. 1994. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem. Biophys. Res. Commun. 200:142–148.

19. Blanco, F., J.R. Ochs, H. Schwarz, and M. Lotz. 1994. Chondrocyte apoptosis induced by nitric oxide: a hypothesis for cartilage degradation. Arthritis & Rheum. 37(Suppl.):S294. (Abstr.)

20. Blanco, F.J., Y. Geng, and M. Lotz. 1995. Differentiation-dependent effects of IL-1 and TGF-β on human articular chondrocyte proliferation are related to inducible nitric oxide synthase expression. J. Immunol. 154:4018–4026.

21. Hall, A.V., H. Antoniou, Y. Wang, A.H. Cheung, A.M. Arbuz, S.L. Olson, W.C. Lu, C.L. Kau, and P.A. Marsden. 1994. Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J. Biol. Chem. 269:33082–33090.

22. Culcs, M., M. Lafon-Cazal, S. Pietri, and J. Bockaert. 1994. Glutamate receptors induce a burst of superoxide via activation of nitric oxide synthase in arginine-depleted neurons. J. Biol. Chem. 269:12589–12593.

23. Pérez-Mediavilla, L.A., M.J. Lopez-Zabalza, M. Calonge, L. Montuenga, N. Lopez-Moratalla, and E. Santiago. 1995. Inducible nitric oxide synthase in human lymphomononuclear cells activated by synthetic peptides derived from extracellular matrix proteins. FEBS Lett. 357:121–124.

24. Das, P., D.J. Schurman, and R.L. Smith. 1995. Shear stress induces the release of nitric oxide by articular chondrocytes. 41st Annu. Mtg. Orth. Res. Soc. 20:354.

25. Amin, A.R., P. Vyas, M. Attur, J. Leszczynska-Pizjik, I.R. Patel, G. Weissmann, and S.B. Abramson. 1995. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 92:1926–1930.

26. Adolphe, M., and P. Benya. 1992. Different types of cultured chondrocytes: the in vitro approach to the study of biological regulation. In Biological Regulation of the Chondrocytes. M. Adolphe, editor. CRC Press, Boca Raton, FL. 105–139.

27. Kuruvilla, A.P., R. Shah, G.M. Hochwald, H.D. Liggitt, M.A. Palladino, and G.J. Thorbecke. 1991. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA. 88:2918–2921.